GTC Biotherapeutics (fka GTCB)

[jessellivermore]

"an obvious weakness of the study is that the patients given AT were on average sicker than the non-AT patients"

This is another one of these publish or perish stat papers where a bunch of charts were pulled and a lame paper was concocted. In addition to Dew's comments,, there is no mention of how many of these sicker patients had been tried on heparin.
Since it is pretty widely understood even very small doses of heparin will interfere with AT3's ability to ameliorate some of the toxic effects of sepsis. AT3's ability to bind to crucial cell receptor sites in both the vascular system and the immune system is blocked by heparin. Without disclosing the heparin statis of patients.....the study is meaningless.